Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL313556 | 0.83 | — | — | |
| SCHEMBL3394614 | 0.80 | — | — | |
| SCHEMBL3390537 | 0.77 | — | — | |
| SCHEMBL3391484 | 0.77 | KDM4E (0.31) | — | |
| SCHEMBL3393971 | 0.74 | — | — | |
| SCHEMBL3430039 | 0.74 | RECQL (0.35) | AGXT | |
| SCHEMBL3396150 | 0.72 | LMNA (0.35) | — | |
| SCHEMBL3393880 | 0.71 | CA12 (0.33) | — | |
| SCHEMBL311410 | 0.70 | — | — | |
| SCHEMBL3391849 | 0.70 | CNR2 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093229-B2 | Alkynyl pyrrolo[2,3-d]pyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2012-01-10 | — | — | US | claimed |
| WO-2010117425-A1 | CERTAIN SUBSTITUTED PYRIMIDINES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE | BIOGEN IDEC MA INC. (US) | 2010-10-14 | — | — | WO | claimed |
| US-7799781-B2 | 5,6,7,8-tetrahydropteridine derivatives as HSP90 inhibitors | ASTRAZENECA AB (SE) | 2010-09-21 | — | — | US | claimed |
| US-20090318387-A1 | ALKYNYL PYRROLO[2,3-d]PYRIMIDINES AND RELATED ANALOGS AS HSP90-INHIBITORS | CONFORMA THERAPEUTICS CORPORATION | 2009-12-24 | — | — | US | claimed |
| EP-2109612-A2 | 5,6,7,8-TETRAHYDROPTERIDINE DERIVATIVES AS HSP90 INHIBITORS | AstraZeneca AB (SE) | 2009-10-21 | — | — | EP | claimed |
| WO-2009106745-A2 | METHOD FOR ENANTIO-SELECTIVE PREPARATION OF SULPHOXIDES | SIDEM PHARMA SA (LU) | 2009-09-03 | — | — | WO | claimed |
| US-7544672-B2 | Alkynyl pyrrolo[2,3-d]pyrimidines and related analogs as HSP90-inhibitors | CONFORMA THERAPEUTICS CORPORATION (US) | 2009-06-09 | — | — | US | claimed |
| US-7528251-B2 | Method for enantioselective preparation of sulphoxide derivatives | SIDEM PHARMA SA (LU) | 2009-05-05 | — | — | US | claimed |
| EP-1802620-B1 | METHOD FOR ENANTIOSELECTIVE PREPARATION OF SULPHOXIDE DERIVATIVES | SIDEM PHARMA S A (LU) | 2008-12-17 | — | — | EP | claimed |
| US-20080194572-A1 | 5,6,7,8-TETRAHYDROPTERIDINE DERIVATIVES AS HSP90 INHIBITORS | ASTRAZENECA AB (SE) | 2008-08-14 | — | — | US | claimed |
| US-20060281782-A1 | Method for the enantioselective preparation of sulphoxide derivatives | SIDEM PHARMA (LU) | 2006-12-14 | — | — | US | claimed |
| WO-2006037894-A1 | METHOD FOR ENANTIOSELECTIVE PREPARATION OF SULPHOXIDE DERIVATIVES | SIDEM PHARMA S.A. (LU) | 2006-04-13 | — | — | WO | claimed |
| EP-0883622-B1 | PROTON PUMP INHIBITOR | APOTEX INC (CA) | 2002-05-15 | — | — | EP | claimed |
| US-6093738-A | IMIDAZO(1,2-D)-THIADIAZOLE COMPOUNDS; PEPTIC ULCER TREATMENT | KARIMIAN KHASHAYAR (CA) | 2000-07-25 | — | — | US | claimed |
| CN-1216527-A | Method for scavenging mercaptan | APOTEX INC (CA) | 1999-05-12 | — | — | CN | claimed |
| EP-0883622-A1 | PROTON PUMP INHIBITOR | APOTEX INC. (CA) | 1998-12-16 | — | — | EP | claimed |
| EP-0883606-A1 | PROCESS FOR SCAVENGING THIOLS | APOTEX INC. (CA) | 1998-12-16 | — | — | EP | claimed |
| US-5677302-A | Thiadiazole compounds useful as proton pump inhibitors | APOTEX INC. (CA) | 1997-10-14 | — | — | US | claimed |
| WO-1997031923-A1 | PROTON PUMP INHIBITOR | APOTEX INC. (CA) | 1997-09-04 | — | — | WO | claimed |
| WO-1997031893-A1 | PROCESS FOR SCAVENGING THIOLS | APOTEX INC. (CA) | 1997-09-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194572-A1 | 5,6,7,8-TETRAHYDROPTERIDINE DERIVATIVES AS HSP90 INHIBITORS | HSP90AA1, HSP90AB1, HSP90AB2P | AGXT 4152/4885ACHE 4476/4885 |
| US-20090318387-A1 | ALKYNYL PYRROLO[2,3-d]PYRIMIDINES AND RELATED ANALOGS AS HSP90-INHIBITORS | HSP90AB2P, HSP90AB1, HSP90AA1 | AGXT 2737/4885ACHE 4879/4885 |
| US-20060281782-A1 | Method for the enantioselective preparation of sulphoxide derivatives | TST, CYP2B6, SQOR | AGXT 3327/4885ACHE 1966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.